Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate’s lead program, AV-101, is a proprietary dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension that is designed to deliver the drug directly to diseased lung tissues, while limiting systemic exposure, and is intended to address the underlying drivers of disease. Aerovate went public in June 2021 and trades on the NASDAQ: AVTE.
| Headquarters | Boston, MA |
| Website | www.aerovatetx.com |
| Pipeline status | Clinical |
| Aerovate Therapeutics |